| Serial Number | 79266778 |
| Word Mark | NUMAB |
| Filing Date | Wednesday, November 28, 2018 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, February 23, 2021 |
| Registration Number | 6274672 |
| Registration Date | Tuesday, February 23, 2021 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 8, 2020 |
| Goods and Services | Chemicals, biochemicals, biological preparations and enzymes from biotechnological processes for use in industry and science; chemicals, biochemicals, biological preparations and enzymes, antibodies and antibody fragments, from biotechnological processes, for development and manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof; biological products comprising monoclonal antibodies and/or derivatives thereof, namely, antibodies and antibody fragments for use in laboratories, diagnosis and analysis for scientific and research purposes; chemical and biochemical additives, carriers and substances for manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof |
| Goods and Services | Pharmaceutical comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases and other pathologies, treatable or improvable through use of antibodies that bind to, activate or block the target antigens; medicines comprising monoclonal antibodies and/or derivatives thereof for human medicine for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; medicines comprising monoclonal antibodies and/or derivatives thereof for veterinary use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical pharmaceutical products comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; diagnostic preparations for medical use comprising monoclonal antibodies and/or derivatives thereof; chemical preparations comprising monoclonal antibodies and/or derivatives thereof for pharmaceutical use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical preparations for veterinary use comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases |
| Goods and Services | Research and development services in the field of pharmaceutical preparations, biotechnology, antibodies and antibody fragments, proteins, micro-organisms and cells for therapeutic purposes; research services with respect to pharmaceutical preparations, biotechnology, antibody therapy and gene therapy; scientific and technological services of a chemical and molecular biological laboratory; research, product development and quality control services in the field of pharmacy, medical diagnostics and medical therapy; research services in the field of chemistry and biology; industrial analysis and research services in the field of pharmacy, medical diagnosis, and medical therapy; research and development services for antibody products for therapeutic purposes; conducting and preparing chemical, biochemical and biotechnological analysis and research |
| Goods and Services | Medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the fields of immuno-oncology, oncology and immunology; provision of medical information; Medical service featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the nature of preparation and administration of medicines in the field of immuno-oncology, oncology and immunology; advice in connection with dietetics and nutrition; advice with respect to health and provision of health information in the fields of immuno-oncology, oncology and immunology; veterinary services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; hygienic and beauty care for humans and animals; provision of information on diagnostic, prophylactic and therapeutic properties of drugs in the fields of immuno-oncology, oncology and immunology |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 13, 2019 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 13, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 13, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 13, 2019 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Numab Therapeutics AG |
| Party Type | 31 - New Owner After Registration |
| Legal Entity Type | 99 - Other |
| Address | CH |
| Party Name | Numab Therapeutics AG |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 25 - NOT AVAILABLE |
| Address | CH-8820 Wädenswil CH |
| Party Name | Numab Therapeutics AG |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 25 - NOT AVAILABLE |
| Address | CH-8820 Wädenswil CH |
| Party Name | Numab Therapeutics AG |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 25 - NOT AVAILABLE |
| Address | CH-8820 Wädenswil CH |
| Party Name | Numab Therapeutics AG |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 25 - NOT AVAILABLE |
| Address | CH |
| Party Name | Numab Innovation AG |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | CH |
| Event Date | Event Description |
| Friday, August 27, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Sunday, June 13, 2021 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Sunday, June 6, 2021 | CHANGE OF OWNER RECEIVED FROM IB |
| Wednesday, May 26, 2021 | FINAL DISPOSITION NOTICE SENT TO IB |
| Wednesday, May 26, 2021 | FINAL DISPOSITION PROCESSED |
| Sunday, May 23, 2021 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Monday, March 1, 2021 | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Sunday, February 28, 2021 | CORRECTION TRANSACTION RECEIVED FROM IB |
| Tuesday, February 23, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, December 8, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 8, 2020 | PUBLISHED FOR OPPOSITION |
| Sunday, December 6, 2020 | NOTIFICATION PROCESSED BY IB |
| Wednesday, November 18, 2020 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, November 18, 2020 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, November 18, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Friday, October 30, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, October 13, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, October 13, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, October 13, 2020 | ASSIGNED TO LIE |
| Tuesday, September 1, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, March 6, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, March 6, 2020 | NON-FINAL ACTION E-MAILED |
| Friday, March 6, 2020 | NON-FINAL ACTION WRITTEN |
| Friday, February 14, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, February 13, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, February 13, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, February 14, 2020 | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Friday, February 7, 2020 | CORRECTION TRANSACTION RECEIVED FROM IB |
| Thursday, November 14, 2019 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Saturday, October 19, 2019 | REFUSAL PROCESSED BY IB |
| Saturday, September 28, 2019 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, September 28, 2019 | REFUSAL PROCESSED BY MPU |
| Wednesday, September 18, 2019 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, September 17, 2019 | NON-FINAL ACTION WRITTEN |
| Tuesday, September 17, 2019 | APPLICATION FILING RECEIPT MAILED |
| Friday, September 13, 2019 | ASSIGNED TO EXAMINER |
| Friday, September 13, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Thursday, September 5, 2019 | SN ASSIGNED FOR SECT 66A APPL FROM IB |